Abstract
Current biological and pharmacological evidence suggests that the melanocortin 4 and melanocortin 3 receptors which are seven transmembrane G-protein coupled receptors (GPCRs) are involved in various aspects of energy balance and feeding behaviors in animals including humans. The natural endogenous ligands for these receptors are products of the gene pro-opiomelanocortin (POMC), and include α-melanocyte stimulating hormone, γ-melanocyte stimulating hormone and perhaps other modified products of POMC. Thus well designed agonists and antagonists of these ligands might serve as drugs for the treatment of feeding disorders. However, these melanotropin peptides also can have other biological activities that involve the MC3R and MC4R, and these other biological properties will need to be modulated in ligands that are likely to be useful drugs for feeding disorders. Current progress in these areas with special emphasis on the MC3R will be discussed along with possible new directions that might be fruitful in these important aspects of contemporary biology and medicine.
Keywords: Melanocortin genes, melanotropin peptides, MC4R, MC3R, obesity, anorexia
Current Topics in Medicinal Chemistry
Title: Melanotropins as Drugs for the Treatment of Obesity and Other Feeding Disorders: Potential and Problems
Volume: 9 Issue: 6
Author(s): Minying Cai, Joel Nyberg and Victor J. Hruby
Affiliation:
Keywords: Melanocortin genes, melanotropin peptides, MC4R, MC3R, obesity, anorexia
Abstract: Current biological and pharmacological evidence suggests that the melanocortin 4 and melanocortin 3 receptors which are seven transmembrane G-protein coupled receptors (GPCRs) are involved in various aspects of energy balance and feeding behaviors in animals including humans. The natural endogenous ligands for these receptors are products of the gene pro-opiomelanocortin (POMC), and include α-melanocyte stimulating hormone, γ-melanocyte stimulating hormone and perhaps other modified products of POMC. Thus well designed agonists and antagonists of these ligands might serve as drugs for the treatment of feeding disorders. However, these melanotropin peptides also can have other biological activities that involve the MC3R and MC4R, and these other biological properties will need to be modulated in ligands that are likely to be useful drugs for feeding disorders. Current progress in these areas with special emphasis on the MC3R will be discussed along with possible new directions that might be fruitful in these important aspects of contemporary biology and medicine.
Export Options
About this article
Cite this article as:
Cai Minying, Nyberg Joel and Hruby J. Victor, Melanotropins as Drugs for the Treatment of Obesity and Other Feeding Disorders: Potential and Problems, Current Topics in Medicinal Chemistry 2009; 9 (6) . https://dx.doi.org/10.2174/156802609788897817
DOI https://dx.doi.org/10.2174/156802609788897817 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Significance of Endothelium-Derived Hyperpolarizing Factor in the Human Circulation
Current Vascular Pharmacology Chest Pain in Children
Current Pediatric Reviews Targeting Host Factors to Circumvent Anti-Malarial Drug Resistance
Current Pharmaceutical Design Mechanisms of Cardiovascular Changes in an Experimental Model of Syndrome X and Pharmacological Intervention on the Renin-Angiotensin- System
Current Vascular Pharmacology Cardiovascular Disease in the Systemic Vasculitides
Current Vascular Pharmacology Mineralocorticoid Receptor Antagonists in Cardiovascular Medicine: Looking for the Forest Among the Trees
Current Pharmaceutical Design Pulmonary Hamartoma: Curative Laser Resection
Current Respiratory Medicine Reviews Current Tools and Methods in Molecular Dynamics (MD) Simulations for Drug Design
Current Medicinal Chemistry Natural Fused Heterocyclic Flavonoids: Potent Candidates as Anti- Inflammatory and Anti-Allergic Agents in the Treatment of Asthma
Current Bioactive Compounds Biomarkers in Lone Atrial Fibrillation-An Additional ‘Fine Tuning’ of Risk?
Current Pharmaceutical Design Herbal Medicine of the 21st Century: A Focus on the Chemistry, Pharmacokinetics and Toxicity of Five Widely Advocated Phytotherapies
Current Topics in Medicinal Chemistry Do RAS Inhibitors Protect the Brain from Cerebral Ischemic Injury?
Current Hypertension Reviews Gene-Wide Approach: New Frontiers in Cardiovascular Genetic Epidemiology
Current Hypertension Reviews Cholesterol Ester Transfer Protein (CETP), Postprandial Lipemia and Hypolipidemic Drugs
Current Medicinal Chemistry Effects of Pterostilbene on Diabetes, Liver Steatosis and Serum Lipids
Current Medicinal Chemistry Case Report: Severe Hematological, Muscle and Liver Toxicity Caused by Drugs and Artichoke Infusion Interaction in an Elderly Polymedicated Patient
Current Drug Safety The NOX1/4 Inhibitor GKT136901 as Selective and Direct Scavenger of Peroxynitrite
Current Medicinal Chemistry Evaluation of the Influence of Splitting on Content Uniformity of Captopril Tablets
Current Pharmaceutical Analysis Autoimmune Diseases and Atherosclerosis: The Inflammatory Connection
Current Immunology Reviews (Discontinued) Personalized Medicine in Psoriasis: Concept and Applications
Current Vascular Pharmacology